These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 26893067)

  • 21. The Research Progress of Direct KRAS G12C Mutation Inhibitors.
    Yang A; Li M; Fang M
    Pathol Oncol Res; 2021; 27():631095. PubMed ID: 34257597
    [No Abstract]   [Full Text] [Related]  

  • 22. Discovery of a Covalent Inhibitor of KRAS
    Lanman BA; Allen JR; Allen JG; Amegadzie AK; Ashton KS; Booker SK; Chen JJ; Chen N; Frohn MJ; Goodman G; Kopecky DJ; Liu L; Lopez P; Low JD; Ma V; Minatti AE; Nguyen TT; Nishimura N; Pickrell AJ; Reed AB; Shin Y; Siegmund AC; Tamayo NA; Tegley CM; Walton MC; Wang HL; Wurz RP; Xue M; Yang KC; Achanta P; Bartberger MD; Canon J; Hollis LS; McCarter JD; Mohr C; Rex K; Saiki AY; San Miguel T; Volak LP; Wang KH; Whittington DA; Zech SG; Lipford JR; Cee VJ
    J Med Chem; 2020 Jan; 63(1):52-65. PubMed ID: 31820981
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Killing tumors by keeping ras and PI3' kinase apart.
    Yuan TL; McCormick F
    Cancer Cell; 2013 Nov; 24(5):562-3. PubMed ID: 24229705
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hitting KRAS When It's Down.
    Gabizon R; London N
    J Med Chem; 2020 Jul; 63(13):6677-6678. PubMed ID: 32568546
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Covalent inhibitors of the GTPase KRAS
    Kettle JG; Cassar DJ
    Expert Opin Ther Pat; 2020 Feb; 30(2):103-120. PubMed ID: 31913776
    [No Abstract]   [Full Text] [Related]  

  • 26. Drug Discovery by Targeting Mutant KRAS.
    Ye N
    Curr Top Med Chem; 2019; 19(23):2079-2080. PubMed ID: 31762422
    [No Abstract]   [Full Text] [Related]  

  • 27. Ras inhibitors display an anti-metastatic effect by downregulation of lysyl oxidase through inhibition of the Ras-PI3K-Akt-HIF-1α pathway.
    Yoshikawa Y; Takano O; Kato I; Takahashi Y; Shima F; Kataoka T
    Cancer Lett; 2017 Dec; 410():82-91. PubMed ID: 28951129
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sticking it to KRAS: Covalent Inhibitors Enter the Clinic.
    McCormick F
    Cancer Cell; 2020 Jan; 37(1):3-4. PubMed ID: 31951561
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structure-Based Design and Pharmacokinetic Optimization of Covalent Allosteric Inhibitors of the Mutant GTPase KRAS
    Kettle JG; Bagal SK; Bickerton S; Bodnarchuk MS; Breed J; Carbajo RJ; Cassar DJ; Chakraborty A; Cosulich S; Cumming I; Davies M; Eatherton A; Evans L; Feron L; Fillery S; Gleave ES; Goldberg FW; Harlfinger S; Hanson L; Howard M; Howells R; Jackson A; Kemmitt P; Kingston JK; Lamont S; Lewis HJ; Li S; Liu L; Ogg D; Phillips C; Polanski R; Robb G; Robinson D; Ross S; Smith JM; Tonge M; Whiteley R; Yang J; Zhang L; Zhao X
    J Med Chem; 2020 May; 63(9):4468-4483. PubMed ID: 32023060
    [TBL] [Abstract][Full Text] [Related]  

  • 30. KRAS
    Cagir A; Azmi AS
    Future Med Chem; 2019 May; 11(9):923-925. PubMed ID: 31140867
    [No Abstract]   [Full Text] [Related]  

  • 31. Distribution of
    Nassar AH; Adib E; Kwiatkowski DJ
    N Engl J Med; 2021 Jan; 384(2):185-187. PubMed ID: 33497555
    [No Abstract]   [Full Text] [Related]  

  • 32. KRAS-targeted therapies in advanced solid cancers: drug the undruggable?
    Saleh K; Kordahi M; Felefly T; Kourie HR; Khalife N
    Pharmacogenomics; 2021 Jul; 22(10):587-590. PubMed ID: 34148378
    [No Abstract]   [Full Text] [Related]  

  • 33. Targeting Mutant KRAS for Immunogenic Cell Death Induction.
    Galluzzi L
    Trends Pharmacol Sci; 2020 Jan; 41(1):1-3. PubMed ID: 31818506
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Small molecule inhibitors of RAS proteins with oncogenic mutations.
    Orgován Z; Keserű GM
    Cancer Metastasis Rev; 2020 Dec; 39(4):1107-1126. PubMed ID: 32770300
    [TBL] [Abstract][Full Text] [Related]  

  • 35. KRAS G12C inhibition with sotorasib in metastatic colorectal cancer.
    Severi C; Van Cutsem E
    Ann Palliat Med; 2022 Aug; 11(8):2792-2795. PubMed ID: 35989651
    [No Abstract]   [Full Text] [Related]  

  • 36. Progress in targeting RAS with small molecule drugs.
    McCormick F
    Biochem J; 2019 Jan; 476(2):365-374. PubMed ID: 30705085
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [CDK4, a specific target in the treatment of lung adenocarcinomas mutated for KRAS].
    Dubus P
    Med Sci (Paris); 2010 Dec; 26(12):1023-5. PubMed ID: 21187034
    [No Abstract]   [Full Text] [Related]  

  • 38. The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
    Fiala O; Pesek M; Finek J; Benesova L; Belsanova B; Minarik M
    Cancer Genet; 2013; 206(1-2):26-31. PubMed ID: 23313110
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Resistance looms for KRAS
    Hata AN; Shaw AT
    Nat Med; 2020 Feb; 26(2):169-170. PubMed ID: 32020086
    [No Abstract]   [Full Text] [Related]  

  • 40. Investigational KRAS Inhibitor Tested for Advanced Solid Tumors.
    Abbasi J
    JAMA; 2020 Nov; 324(18):1818. PubMed ID: 33170223
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.